Chen Yu, M.D., M.B.A.
Chen Yu, M.D., M.B.A. is a Managing Partner who joined Vivo in 2004. Dr.
Yu has extensive operating experience in a broad array of industries
with stints at China KangHui, aQuantive, Eli Lilly, and Bain & Co. Most
recently, as Chief Business Officer at KangHui (KH), he helped take the
company public on the New York Stock Exchange in the most successful
healthcare IPO of 2010. At Vivo, his interest is in both medical device
and pharmaceutical companies and he currently serves on the boards of
several life science companies, including Sagent Pharmaceuticals (SGNT),
KSPC Pharmaceuticals (a Chinese joint venture with Sagent
Pharmaceuticals and KangHong Pharmaceuticals), Rempex, Nora
Therapeutics, and Synaptic Medical, a China based medical device
company. Other investments include Achillion (ACHN), Cubist (CBST), and
Tranzyme (TZYM). Dr. Yu is also a member of the Stanford Medical School
Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from
Stanford University and graduated magna cum laude with a B.A. in Biology
from Harvard University.